share_log

NexImmune | DEF 14A: Definitive information statements

NexImmune | DEF 14A: Definitive information statements

NexImmune | DEF 14A：股東委託書決議
美股SEC公告 ·  06/21 07:36
Moomoo AI 已提取核心訊息
NexImmune, Inc., a biopharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on July 11, 2024, to vote on the company's dissolution and subsequent liquidation. The meeting follows a series of adjournments due to insufficient quorum and explores the dissolution as the company's efforts to secure additional financing have been unsuccessful. The Board has recommended the liquidation plan, which includes the sale of common stock and warrants for approximately $3.67 million. The Board believes that alternatives to dissolution are limited and may involve seeking voluntary dissolution later with potentially diminished assets or seeking bankruptcy protection. The company has issued a Series A Preferred Stock to ensure the adoption of the dissolution proposal, assuming the majority of common stock votes are in favor. The Board has unanimously recommended stockholders vote for the dissolution and liquidation plan.
NexImmune, Inc., a biopharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on July 11, 2024, to vote on the company's dissolution and subsequent liquidation. The meeting follows a series of adjournments due to insufficient quorum and explores the dissolution as the company's efforts to secure additional financing have been unsuccessful. The Board has recommended the liquidation plan, which includes the sale of common stock and warrants for approximately $3.67 million. The Board believes that alternatives to dissolution are limited and may involve seeking voluntary dissolution later with potentially diminished assets or seeking bankruptcy protection. The company has issued a Series A Preferred Stock to ensure the adoption of the dissolution proposal, assuming the majority of common stock votes are in favor. The Board has unanimously recommended stockholders vote for the dissolution and liquidation plan.
美國生物製藥公司NexImmune，已宣佈將於2024年7月11日通過虛擬形式召開特別股東大會，就公司的解散和隨後的清算進行投票。此次會議是在公司因未能獲得足夠的法定人數而進行一系列休會後召開的，並探討了解散，因爲公司爭取獲得額外融資的努力未能成功。董事會已經推薦了包括出售普通股和權證在內的清算計劃，總價值約爲367萬美元。董事會認爲，解散除本外無他法，可能需要以潛在的資產減值或尋求破產保護爲代價的自願解散。公司已經發行了A系列優先股以確保解散提案的通過，假定普通股的多數股票持有者支持該提案。董事會一致推薦股東同意解散和清算計劃。
美國生物製藥公司NexImmune，已宣佈將於2024年7月11日通過虛擬形式召開特別股東大會，就公司的解散和隨後的清算進行投票。此次會議是在公司因未能獲得足夠的法定人數而進行一系列休會後召開的，並探討了解散，因爲公司爭取獲得額外融資的努力未能成功。董事會已經推薦了包括出售普通股和權證在內的清算計劃，總價值約爲367萬美元。董事會認爲，解散除本外無他法，可能需要以潛在的資產減值或尋求破產保護爲代價的自願解散。公司已經發行了A系列優先股以確保解散提案的通過，假定普通股的多數股票持有者支持該提案。董事會一致推薦股東同意解散和清算計劃。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息